| the oklahoma-pittsburgh experience with interferon alpha in the treatment of hcv disease. | interferon alpha (ifn) is the only food and drug administration (fda)-approved therapy available for the treatment of chronic hepatitis c. the ideal dose and frequency of ifn administration that produces the greatest number of patient responders with the least number of relapses following drug withdrawal remains unclear. methods. one hundred seventeen patients recruited over a five-year period with chronic hepatitis c were divided into four groups and treated with progressively larger doses. the ... | 1995 | 7782963 |
| part xiv. antiviral agents other than antiretrovirals: therapy for herpesvirus infections, viral hepatitis, and influenza. | the incidences of viral infectious diseases are increasing at an alarming rate in the us and worldwide. antiviral therapy is challenging because viruses subsume normal host cellular mechanisms for many functions, have rapid replication rates, have poor error scanning when reading genetic code, and undergo frequent drug target mutations. this article will focus on antiviral drugs and principles of treatment for infections due to herpes simplex viruses (hsv1 and hsv2), varicella zoster virus (vzv) ... | 2007 | 18085096 |
| outcome of a hepatitis c outbreak among patients in a pain management clinic. | the aims of this study are to evaluate the natural history and response to therapy of patients following a hepatitis c outbreak in a pain management clinic. | 2010 | 20411419 |
| making the best of a bad situation: early chronic nosocomial hcv infection. | | 2010 | 20480237 |